Favipiravir therapy for patients with covid-19 pneumonia: An observational study
Pneumonia in patients with COVID-19 is sometimes severe and life-threatening, and currently there is no specific effective drug approved for COVID-19 treatment. Favipiravir is a pyrazine analog inhibiting RNA virus RNA dependent RNA polymerase with antiviral activity against SARS-CoV-2. An observati...
Saved in:
Main Authors: | , , , , , , , , , |
---|---|
Other Authors: | |
Format: | Article |
Published: |
2022
|
Subjects: | |
Online Access: | https://repository.li.mahidol.ac.th/handle/123456789/78454 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | Mahidol University |
id |
th-mahidol.78454 |
---|---|
record_format |
dspace |
spelling |
th-mahidol.784542022-08-04T18:01:02Z Favipiravir therapy for patients with covid-19 pneumonia: An observational study Supawadee Suppadungsuk Thananya Wongsinin Sirawat Srichatrapimuk Suppachok Kirdlarp Kulapong Jayanama Kanin Thammavaranucupt Dhanesh Pitidhammabhorn Sithakom Phusanti Nithita Nanthatanti Somnuek Sungkanuparph Faculty of Medicine Ramathibodi Hospital, Mahidol University Medicine Pneumonia in patients with COVID-19 is sometimes severe and life-threatening, and currently there is no specific effective drug approved for COVID-19 treatment. Favipiravir is a pyrazine analog inhibiting RNA virus RNA dependent RNA polymerase with antiviral activity against SARS-CoV-2. An observational study was conducted in confirmed COVID-19 pneumonia patients admitted to a university hospital in Thailand on effectiveness and safety of favipiravir prescribed on a compassionate-use basis. Among COVID-19 patients with pneumonia (n = 37), 54 and 46% had severe and non-severe pneumonia, respectively. Mean ± SD age was 48 ± 3 years, 62% were male and diabetes mellitus and hypertension were the most common comorbidities. Median period from initiation of favipiravir treatment to clinical improvement of patients with severe and non-severe pneumonia was 17 days (95% confidence interval (CI): 9-25) and 9 days (95% CI: 7-11) respectively. Ninety-five percent of patients completely recovered and were discharged within 39 days following admittance; unfortunately, the remaining patients succumbed to severe acute respiratory distress syndrome and multi-organ failure. In conclusion, favipiravir holds promise as a potential drug for treatment of COVID-19 pneumonia, but a larger randomized trial is warranted to confirm its efficacy. 2022-08-04T11:01:02Z 2022-08-04T11:01:02Z 2021-02-04 Article Southeast Asian Journal of Tropical Medicine and Public Health. Vol.52, No.1 (2021), 161-174 26975718 01251562 2-s2.0-85119835401 https://repository.li.mahidol.ac.th/handle/123456789/78454 Mahidol University SCOPUS https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85119835401&origin=inward |
institution |
Mahidol University |
building |
Mahidol University Library |
continent |
Asia |
country |
Thailand Thailand |
content_provider |
Mahidol University Library |
collection |
Mahidol University Institutional Repository |
topic |
Medicine |
spellingShingle |
Medicine Supawadee Suppadungsuk Thananya Wongsinin Sirawat Srichatrapimuk Suppachok Kirdlarp Kulapong Jayanama Kanin Thammavaranucupt Dhanesh Pitidhammabhorn Sithakom Phusanti Nithita Nanthatanti Somnuek Sungkanuparph Favipiravir therapy for patients with covid-19 pneumonia: An observational study |
description |
Pneumonia in patients with COVID-19 is sometimes severe and life-threatening, and currently there is no specific effective drug approved for COVID-19 treatment. Favipiravir is a pyrazine analog inhibiting RNA virus RNA dependent RNA polymerase with antiviral activity against SARS-CoV-2. An observational study was conducted in confirmed COVID-19 pneumonia patients admitted to a university hospital in Thailand on effectiveness and safety of favipiravir prescribed on a compassionate-use basis. Among COVID-19 patients with pneumonia (n = 37), 54 and 46% had severe and non-severe pneumonia, respectively. Mean ± SD age was 48 ± 3 years, 62% were male and diabetes mellitus and hypertension were the most common comorbidities. Median period from initiation of favipiravir treatment to clinical improvement of patients with severe and non-severe pneumonia was 17 days (95% confidence interval (CI): 9-25) and 9 days (95% CI: 7-11) respectively. Ninety-five percent of patients completely recovered and were discharged within 39 days following admittance; unfortunately, the remaining patients succumbed to severe acute respiratory distress syndrome and multi-organ failure. In conclusion, favipiravir holds promise as a potential drug for treatment of COVID-19 pneumonia, but a larger randomized trial is warranted to confirm its efficacy. |
author2 |
Faculty of Medicine Ramathibodi Hospital, Mahidol University |
author_facet |
Faculty of Medicine Ramathibodi Hospital, Mahidol University Supawadee Suppadungsuk Thananya Wongsinin Sirawat Srichatrapimuk Suppachok Kirdlarp Kulapong Jayanama Kanin Thammavaranucupt Dhanesh Pitidhammabhorn Sithakom Phusanti Nithita Nanthatanti Somnuek Sungkanuparph |
format |
Article |
author |
Supawadee Suppadungsuk Thananya Wongsinin Sirawat Srichatrapimuk Suppachok Kirdlarp Kulapong Jayanama Kanin Thammavaranucupt Dhanesh Pitidhammabhorn Sithakom Phusanti Nithita Nanthatanti Somnuek Sungkanuparph |
author_sort |
Supawadee Suppadungsuk |
title |
Favipiravir therapy for patients with covid-19 pneumonia: An observational study |
title_short |
Favipiravir therapy for patients with covid-19 pneumonia: An observational study |
title_full |
Favipiravir therapy for patients with covid-19 pneumonia: An observational study |
title_fullStr |
Favipiravir therapy for patients with covid-19 pneumonia: An observational study |
title_full_unstemmed |
Favipiravir therapy for patients with covid-19 pneumonia: An observational study |
title_sort |
favipiravir therapy for patients with covid-19 pneumonia: an observational study |
publishDate |
2022 |
url |
https://repository.li.mahidol.ac.th/handle/123456789/78454 |
_version_ |
1763488457100886016 |